Mae'r JCVI wedi argymell y dylid cyflymu'r rhaglen frechu drwy ddilyn y camau sydd wedi’u nodi isod:mae pob oedolyn sydd dros 18 oed bellach yn gymwys i gael brechiad atgyfnerthu, ond dylid rhoi blaenoriaeth o hyd i oedolion hŷn a'r rheini sydd mewn perygldylai’r cyfnod cyn y cynigir dos atgyfnerthu gael ei leihau i o leiaf dri mis ar ôl cwblhau’r cwrs sylfaenoldylai unigolion sydd â system imiwnedd wan sydd wedi cwblhau eu cwrs sylfaenol o dri dos gael cynnig dos atgyfnerthu, gydag o leiaf dri mis rhwng y trydydd dos sylfaenol a'r dos atgyfnerthu, yn unol â’r cyngor clinigol ar yr amseru gorau posiblni ddylid gwahaniaethu rhwng y brechlynnau Moderna a Pfizer-BioNTech wrth ddewis pa un i’w ddefnyddio fel rhan o’r rhaglen brechiadau atgyfnerthu COVID-19. Dangoswyd bod y ddau frechlyn yn cynyddu lefelau gwrthgyrff yn sylweddol pan fyddant yn cael eu cynnig fel dos atgyfnerthu
The JCVI has recommended an acceleration to the vaccination programme through a number of ways outlined below:all adults over 18 are now eligible for a booster, though priority should still be given to older adults and those at riskbooster doses should be offered at a reduced minimum of three months after completion of the primary courseindividuals who are severely immunosuppressed who have completed their primary course of three doses should be offered a booster dose, with a minimum of three months between the third primary and booster dose, in line with clinical advice on optimal timingboth the Moderna and Pfizer-BioNTech vaccines should be used with equal preference in the COVID-19 booster programme. Both vaccines have been shown to substantially increase antibody levels when offered as a booster dose.